Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron for Maintenance of Body Weight Reduction
NCT06584916Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of orforglipron in obesity, Overweight, sponsored by Eli Lilly and Company. Started Sep 2024; status: completed.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06584916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584916.